Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer

Ann Oncol. 2015 May;26(5):1035-1036. doi: 10.1093/annonc/mdv067. Epub 2015 Feb 10.

Authors

G Rossi¹, L Baldi², F Barbieri³, F Bertolini³, M Tiseo⁴

Affiliations

¹ Section of Pathologic Anatomy, University Hospital Policlinico of Modena, Modena;. Electronic address: giurossi68@gmail.com.
² Department of Oncology and Advanced Technologies, Operative Unit of Oncology, Arcispedale S. Maria Nuova/I.R.C.C.S., Reggio Emilia.
³ Department of Oncology, University Hospital Policlinico of Modena, Modena.
⁴ Division of Medical Oncology University Hospital, Parma, Italy.

PMID: 25669831
DOI: 10.1093/annonc/mdv067

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / genetics*
DNA Mutational Analysis / methods*
Female
Genes, erbB-1*
Humans
Lung Neoplasms / genetics*
Male
Protein Kinase Inhibitors / therapeutic use*
Receptor Protein-Tyrosine Kinases / genetics*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Receptor Protein-Tyrosine Kinases